Actively Recruiting

Age: 18Years +
All Genders
NCT07413757

CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

Led by AstraZeneca · Updated on 2026-04-22

590

Participants Needed

1

Research Sites

21 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.

CONDITIONS

Official Title

CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

The following inclusion criteria must be met in order to be enrolled in the stage 1:

Patient:

  • Provide informed consent
  • 18 years or older
  • Diagnosed with stage IV NSCLC
  • Currently receiving or previously received 1L EGFR-TKI treatment
  • Without communication barrier
  • Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter

Physician:

  • Provide informed consent
  • Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
  • Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
  • Holding the title of associate chief physician or higher

The following inclusion criteria must be met in order to be enrolled in the stage 2:

Patient:

  • Provide informed consent
  • 18 years or older
  • Diagnosed with stage IV NSCLC
  • Currently receiving or previously received 1L EGFR-TKI treatment
  • Without communication barrier
  • Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter

Physician:

  • Provide informed consent
  • Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
  • Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
  • Holding the title of attending physician or higher
Not Eligible

You will not qualify if you...

Not applicable.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Research Site

Chengdu, China, 610000

Actively Recruiting

Loading map...

Research Team

A

AstraZeneca Clinical Study Information Center

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here